Asset Details
Do you wish to reserve the book?
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Do you wish to request the book?
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
2009
Overview
Objective To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease.Design Meta-analysis of randomised controlled trials.Data sources Medline (1966-November 2008), the Cochrane central register of controlled trials (Cochrane Library 2008;issue 4), and reference lists of retrieved articles.Review methods Randomised trials of aspirin compared with placebo or no aspirin in people with diabetes and no pre-existing cardiovascular disease were eligible for inclusion. Data on major cardiovascular events (death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, and all cause mortality) were extracted and pooled with a random effect model. Results are reported as relative risks with 95% confidence intervals.Results Of 157 studies in the literature searches, six were eligible (10 117 participants). When aspirin was compared with placebo there was no statistically significant reduction in the risk of major cardiovascular events (five studies, 9584 participants; relative risk 0.90, 95% confidence interval 0.81 to 1.00), cardiovascular mortality (four studies, n=8557, 0.94; 0.72 to 1.23), or all cause mortality (four studies, n=8557; 0.93, 0.82 to 1.05). Significant heterogeneity was found in the analysis for myocardial infarction (I2=62.2%; P=0.02) and stroke (I2=52.5%; P=0.08). Aspirin significantly reduced the risk of myocardial infarction in men (0.57, 0.34 to 0.94) but not in women (1.08, 0.71 to 1.65; P for interaction=0.056). Evidence relating to harms was inconsistent.Conclusions A clear benefit of aspirin in the primary prevention of major cardiovascular events in people with diabetes remains unproved. Sex may be an important effect modifier. Toxicity is to be explored further.
Publisher
British Medical Journal Publishing Group,British Medical Association,BMJ Publishing Group LTD,BMJ Publishing Group Ltd
Subject
/ Aspirin - administration & dosage
/ Cardiovascular Agents - administration & dosage
/ Cardiovascular Agents - adverse effects
/ Clinical Trials (Epidemiology)
/ Diabetes
/ Diabetic Angiopathies - prevention & control
/ Drugs: Cardiovascular System
/ Female
/ Humans
/ Internet
/ Male
/ Placebos
/ Randomized Controlled Trials as Topic
/ Stroke
